Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Renal denervation in the antihypertensive arsenal – knowns and known unknowns
Brguljan, Jana , Ferdinand, Keith C. , Laffer, Cheryl L. , Ram, C. Venkata S. , Shalaeva, E. , Textor, Stephen C., Vongpatanasin, Wanpen , Vogt, Liffert , Wang, Ji‐Guang , Williams, Bryan , Messerli, Franz H. , Bavishi, Chirag , Burnier, Michel , Dobner, Stephan , Elijovich, Fernando , Kjeldsen, Sverre Erik , Rexhaj, Emrush , Ruilope, Luis Miguel , Siontis, George C.M. , Staessen, Jan A , Volpe, Massimo

Mayo Clinic

Journal of Hypertension | September 2, 2022 | Volume: 40 | Issue: 10 | Pages: 1859-1875

10.1097/hjh.0000000000003171 | PMID 36052518 Get It

Even though it has been more than a decade since renal denervation (RDN) was first used to treat hypertension and an intense effort on researching this therapy has been made, it is still not clear how RDN fits into the antihypertensive arsenal. There is no question that RDN lowers blood pressure (BP), it does so to an extent at best corresponding to one antihypertensive drug. The procedure has an excellent safety record. However, it remains clinically impossible to predict whose BP responds to RDN and whose does not. Long-term efficacy data on BP reduction are still unconvincing despite the recent results in the SPYRAL HTN-ON MED trial; experimental studies indicate that reinnervation is occurring after RDN. Although BP is an acceptable surrogate endpoint, there is complete lack of outcome data with RDN. Clear indications for RDN are lacking although patients with resistant hypertension, those with documented increase in activity of the sympathetic system and perhaps those who desire to take fewest medication may be considered.
Decreased Gut Microbiome Tryptophan Metabolism and Serotonergic Signaling in Patients With Persistent Mental Health and Gastrointestinal Symptoms After COVID-19
Blackett, John W. , Sun, Yiwei , Elkind, Mitchell S.V. , O’Byrne, Sheila M., Freedberg, Daniel E. , Purpura, Lawrence J. , Margolis, Kara Gross , Wainberg, Milton L. , Abrams, Julian A , Wang, Harris H. , Chang, Lin

Mayo Clinic

Clinical and Translational Gastroenterology | September 1, 2022 | Volume: 13 | Issue: 10 | Pages: e00524

10.14309/ctg.0000000000000524 | PMID 36049050 Get It

INTRODUCTION: An estimated 15%–29% of patients report new gastrointestinal (GI) symptoms after coronavirus-19 disease (COVID-19) while 4%–31% report new depressive symptoms. These symptoms may be secondary to gut microbiome tryptophan metabolism and 5-hydroxytryptamine (5-HT)-based signaling. METHODS: This study used specimens from 2 patient cohorts: (i) fecal samples from patients with acute COVID-19 who participated in a randomized controlled trial testing prebiotic fiber and (ii) blood samples from patients with acute COVID-19. Six months after recovering from COVID-19, both cohorts answered questions related to GI symptoms and anxiety or depression. Microbiome composition and function, focusing on tryptophan metabolism-associated pathways, and plasma 5-HT were assessed. RESULTS: In the first cohort (n = 13), gut microbiome L-tryptophan biosynthesis during acute COVID-19 was decreased among those who developed more severe GI symptoms (2.0-fold lower log activity comparing those with the most severe GI symptoms vs those with no symptoms, P = 0.06). All tryptophan pathways showed decreased activity among those with more GI symptoms. The same pathways were also decreased in those with the most severe mental health symptoms after COVID-19. In an untargeted analysis, 5 additional metabolic pathways significantly differed based on subsequent development of GI symptoms. In the second cohort (n = 39), plasma 5-HT concentration at the time of COVID-19 was increased 5.1-fold in those with GI symptoms alone compared with those with mental health symptoms alone ( P = 0.02). DISCUSSION: Acute gut microbiome-mediated reduction in 5-HT signaling may contribute to long-term GI and mental health symptoms after COVID-19. Future studies should explore modification of 5-HT signaling to reduce post-COVID symptoms.
AACC Guidance Document on the Use of Point-of-Care Testing in Fertility and Reproduction
Nichols, James H. , Ali, Mahesheema , Anetor, John I. , Chen, Li Sheng, Chen, Yu , Das, Saswati , Karon, Brad S. , Kary, Heba, Nerenz, Robert D , Rai, Alex J, Shajani-Yi, Zahra, Thakur, Vinita , Wang, Sihe , Yu, Hoi Ying Elsie, Zamora, Lindsey E , Das, Saswati , Nichols, James H , Collins, Sean P. , Devaraj, Sridevi , Fu, Lei , Rai, Alex J

Mayo Clinic

The Journal of Applied Laboratory Medicine | September 1, 2022 | Volume: 7 | Issue: 5 | Pages: 1202-1236

10.1093/jalm/jfac042 | PMID 36047824 Get It

Abstract Background The AACC Academy revised the reproductive testing section of the Laboratory Medicine Practice Guidelines: Evidence-Based Practice for Point-of-Care Testing (POCT) published in 2007. Methods A panel of Academy members with expertise in POCT and laboratory medicine was formed to develop guidance for the use of POCT in reproductive health, specifically ovulation, pregnancy, premature rupture of membranes (PROM), and high-risk deliveries. The committee was supplemented with clinicians having Emergency Medicine and Obstetrics/Gynecology training. Results Key recommendations include the following. First, urine luteinizing hormone (LH) tests are accurate and reliable predictors of ovulation. Studies have shown that the use of ovulation predicting kits may improve the likelihood of conception among healthy fertile women seeking pregnancy. Urinary LH point-of-care testing demonstrates a comparable performance among other ovulation monitoring methods for timing intrauterine insemination and confirming sufficient ovulation induction before oocyte retrieval during in vitro fertilization. Second, pregnancy POCT should be considered in clinical situations where rapid diagnosis of pregnancy is needed for treatment decisions, and laboratory analysis cannot meet the required turnaround time. Third, PROM testing using commercial kits alone is not recommended without clinical signs of rupture of membranes, such as leakage of amniotic fluid from the cervical opening. Finally, fetal scalp lactate is used more than fetal scalp pH for fetal acidosis due to higher success rate and low volume of sample required. Conclusions This revision of the AACC Academy POCT guidelines provides recommendations for best practice use of POCT in fertility and reproduction.
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Deng, Jing , Paulus, Aneel , Fang, Douglas D. , Manna, Alak , Wang, Guangfeng , Wang, Hengbang , Zhu, Saijie , Chen, Jianyong , Min, Ping , Yin, Yan , Dutta, Navnita , Halder, Nabanita , Ciccio, Gina , Copland, John A. , Miller, James L. , Han, Bing , Bai, Longchuan , Liu, Liu , Wang, Mi , McEachern, Donna , Przybranowski, Sally , Yang, Chao‐Yie , Stuckey, Jeanne A. , Li, Caixia , Letai, Anthony , Yang, Dajun , Wang, Shaomeng , Chanan‐Khan, Asher , Miller, James , Wu, Depei , Li, Caixia , Ryan, Jeremy , Letai, Anthony , Ailawadhi, Sikander , Yang, Dajun , Wang, Shaomeng , Chanan-Khan, Asher , Zhai, Yifan , Paulus, Aneel , Ryan, Jeremy , Ailawadhi, Sikander

Mayo Clinic

Clinical Cancer Research | September 1, 2022 | Volume: 28 | Issue: 24 | Pages: 5455-5468

10.1158/1078-0432.ccr-21-4037 | PMID 36048524 Get It

Abstract Purpose: Development of B-cell lymphoma 2 (BCL-2)–specific inhibitors poses unique challenges in drug design because of BCL-2 homology domain 3 (BH3) shared homology between BCL-2 family members and the shallow surface of their protein–protein interactions. We report herein discovery and extensive preclinical investigation of lisaftoclax (APG-2575). Experimental Design: Computational modeling was used to design “lead” compounds. Biochemical binding, mitochondrial BH3 profiling, and cell-based viability or apoptosis assays were used to determine the selectivity and potency of BCL-2 inhibitor lisaftoclax. The antitumor effects of lisaftoclax were also evaluated in several xenograft models. Results: Lisaftoclax selectively binds BCL-2 (Ki < 0.1 nmol/L), disrupts BCL-2:BIM complexes, and compromises mitochondrial outer membrane potential, culminating in BAX/BAK-dependent, caspase-mediated apoptosis. Lisaftoclax exerted strong antitumor activity in hematologic cancer cell lines and tumor cells from patients with chronic lymphocytic leukemia, multiple myeloma, or Waldenström macroglobulinemia. After lisaftoclax treatment, prodeath proteins BCL-2‒like protein 11 (BIM) and Noxa increased, and BIM translocated from cytosol to mitochondria. Consistent with these apoptotic activities, lisaftoclax entered malignant cells rapidly, reached plateau in 2 hours, and significantly downregulated mitochondrial respiratory function and ATP production. Furthermore, lisaftoclax inhibited tumor growth in xenograft models, correlating with caspase activation, poly (ADP-ribose) polymerase 1 cleavage, and pharmacokinetics of the compound. Lisaftoclax combined with rituximab or bendamustine/rituximab enhanced antitumor activity in vivo. Conclusions: These findings demonstrate that lisaftoclax is a novel, orally bioavailable BH3 mimetic BCL-2–selective inhibitor with considerable potential for the treatment of certain hematologic malignancies.
Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer
Katsuta, Eriko , Takabe, Kazuaki , Vujcic, Marija, Dai, Tao , Mercado‐Perez, Arnaldo , Beyder, Arthur, Wang, Qingfei , Opyrchal, Mateusz , Mercado-Perez, Arnaldo, Wang, Qingfei , Opyrchal, Mateusz , Gottlieb, Philip A.

Mayo Clinic

International Journal of Molecular Sciences | September 1, 2022 | Volume: 23 | Issue: 17 | Pages: 9909

10.3390/ijms23179909 | PMID 36077309 Get It

Background: Mechanically gated PIEZO channels lead to an influx of cations, activation of additional Ca2+ channels, and cell depolarization. This study aimed to investigate PIEZO2’s role in breast cancer. Methods: The clinical relevance of PIEZO2 expression in breast cancer patient was analyzed in a publicly available dataset. Utilizing PIEZO2 overexpressed breast cancer cells, and in vitro and in vivo experiments were conducted. Results: High expression of PIEZO2 was correlated with a worse survival in triple-negative breast cancer (TNBC) but not in other subtypes. Increased PEIZO2 channel function was confirmed in PIEZO2 overexpressed cells after mechanical stimulation. PIEZO2 overexpressed cells showed increased motility and invasive phenotypes as well as higher expression of SNAIL and Vimentin and lower expression of E-cadherin in TNBC cells. Correspondingly, high expression of PIEZO2 was correlated with the increased expression of epithelial–mesenchymal transition (EMT)-related genes in a TNBC patient. Activated Akt signaling was observed in PIEZO2 overexpressed TNBC cells. PIEZO2 overexpressed MDA-MB-231 cells formed a significantly higher number of lung metastases after orthotopic implantation. Conclusion: PIEZO2 activation led to enhanced SNAIL stabilization through Akt activation. It enhanced Vimentin and repressed E-cadherin transcription, resulting in increased metastatic potential and poor clinical outcomes in TNBC patients.
Sulfotransferase (sult) 1A1 pharmacogenetics: Functional 5′‐flanking region (5′‐FR) polymorphisms
Prondzinski, Janel L, Thomae, Bianca A., Wang, L., Eckloff, Bruce W., Wieben, Eric D. , Weinshilboum, Richard

Mayo Clinic

Clinical Pharmacology & Therapeutics | August 31, 2022 | Volume: 73 | Issue: 2 | Pages: No page available

10.1016/s0009-9236(03)90641-2b Get It

Clinical Pharmacology & Therapeutics (2003) 73, P77–P77; doi:
Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer
Kohale, Ishwar N. , Yu, Jia , Zhuang, Yongxian , Fan, Xiaoyang , Reddy, Raven J. , Carter, Jodi M. , Goetz, Matthew P. , Wang, Liewei , White, Forest M. , Sinnwell, Jason, White, Forest M , Goetz, Matthew P , Carter, Jodi , Sinnwell, Jason P. , Kalari, Krishna R. , Boughey, Judy C.

Mayo Clinic

Cancers | August 30, 2022 | Volume: 14 | Issue: 17 | Pages: 4220

10.3390/cancers14174220 | PMID 36077757 Get It

Neoadjuvant chemotherapy (NAC) remains the cornerstone of the treatment for triple negative breast cancer (TNBC), with the goal of complete eradication of disease. However, for patients with residual disease after NAC, recurrence and mortality rates are high and the identification of novel therapeutic targets is urgently needed. We quantified tyrosine phosphorylation (pTyr)-mediated signaling networks in chemotherapy sensitive (CS) and resistant (CR) TNBC patient-derived xenografts (PDX), to gain novel therapeutic insights. The antitumor activity of SFK inhibition was examined in vivo. Treated tumors were further subjected to phosphoproteomic and RNAseq analysis, to identify the mechanism of actions of the drug. We identified Src Family Kinases (SFKs) as potential therapeutic targets in CR TNBC PDXs. Treatment with dasatinib, an FDA approved SFK inhibitor, led to inhibition of tumor growth in vivo. Further analysis of post-treatment PDXs revealed multiple mechanisms of actions of the drug, confirming the multi-target inhibition of dasatinib. Analysis of pTyr in tumor specimens suggested a low prevalence of SFK-driven tumors, which may provide insight into prior clinical trial results demonstrating a lack of dasatinib antitumor activity in unselected breast cancer patients. Taken together, these results underscore the importance of pTyr characterization of tumors, in identifying new targets, as well as stratifying patients based on their activated signaling networks for therapeutic options. Our data provide a strong rationale for studying SFK inhibitors in biomarker-selected SFK-driven TNBC.
Depression: A Modifiable Risk Factor for Poor Outcomes in Fibromyalgia
Munipalli, Bala , Allman, Madeleine , Chauhan, Mohit , Niazi, Shehzad K. , Rivera, Fernando, Abril, Andy , Wieczorek, Mikolaj A. , Hodge, David O. , Dudenkov, Daniel V. , Bruce, Barbara K. , Knight, Dacre , Perlman, Adam , Dudenkov, Daniel, Chauhan, Mohit , Rivera, Fernando, Wang, Benjamin X. , Knight, Dacre R T , Perlman, Adam , Dabrh, Abd Moain Abu

Mayo Clinic

Journal of Primary Care & Community Health | August 29, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221120738 | PMID 36036260 Get It

Background: About 4 out of 10 fibromyalgia patients suffer from depression. The European Alliance of Associations for Rheumatology (EULAR) guidelines recommend using antidepressants to treat fibromyalgia. Objective: To determine predictors of improved outcomes following a multicomponent treatment program. Design: We designed this longitudinal treatment outcome study to evaluate the prevalence of depression symptoms in patients diagnosed with fibromyalgia at a tertiary care facility, and the impact of depression on functional outcomes after completing a multicomponent fibromyalgia treatment program. Setting: Tertiary care center. Patients: This study included 411 adult patients with fibromyalgia who completed a multicomponent treatment program for fibromyalgia. Expert physicians performed comprehensive evaluations following American College of Rheumatology (ACR) criteria to confirm fibromyalgia before referral to the program. Intervention: An intensive outpatient multicomponent treatment program consisting of 16 hours of cognitive behavioral strategies served as the intervention. Measurements: Functional status was assessed using the Fibromyalgia Impact Questionnaire Revised (FIQR). Depression was evaluated with the Center for Epidemiologic Study of Depression (CES-D) measure. Measures were administered prior to participation in the program and approximately 5 months following completion of the program. Results: The cohort had a high prevalence of depressive symptoms (73.2% had depression at admission). Higher depression scores at baseline predicted poorer outcomes following multi-component treatment. Effectively treated depression resulted in improved functioning at follow-up. Limitations: Findings limited to tertiary care center cohort of fibromyalgia patients. Patients did not undergo a structured clinical diagnostic interview to diagnose depression. Conclusions: The current data links depression to poorer outcomes in patients with fibromyalgia. Depression is an important modifiable factor in the management of fibromyalgia. Guidelines should reflect the importance of assessing and effectively treating depression at the time of diagnosis of fibromyalgia, to improve functional outcomes. Registration: Specific registry and specific study registration number—Institutional Review Board—(IRB# 19-000495). Funding Source: No funding.
Physical activity and the risk of non‐Hodgkin lymphoma subtypes: A pooled analysis
Boyle, Terry , Kleinstern, Geffen , Bracci, Paige M. , Cerhan, James R. , Benavente, Yolanda , Casabonne, Delphine , Holly, Elizabeth A., Liebow, Mark , Paltiel, Ora , Robinson, Dennis P. , Rothman, Nathaniel , Wang, Sophia , Weisenburger, Dennis D. , Spinelli, John J., Norman, Aaron, Paltiel, Ora , Robinson, Dennis, Rothman, Nathaniel , Cerhan, James R , Wang, Sophia S , Chiu, Brian C.‐H. , Habermann, Thomas M. , Norman, Aaron D. , Rothman, Nathaniel , Seir, Rania Abu , Slager, Susan L. , Villeneuve, Paul J.

Mayo Clinic

International Journal of Cancer | August 27, 2022 | Volume: 152 | Issue: 3 | Pages: 396-407

10.1002/ijc.34266 | PMID 36054546 Get It

AbstractNon‐Hodgkin lymphoma (NHL) is composed of a heterogeneous collection of subtypes with considerable differences in genetics, biology and aetiology. Studies to date on physical activity and NHL risk have not had sufficient sample size to evaluate whether associations differ by subtype. We pooled data from nine case‐control studies to examine the association between moderate‐to‐vigorous intensity physical activity (MVPA) and risk of NHL overall and by subtype (diffuse large B‐cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, marginal zone lymphoma and mature T‐cell lymphoma). A total of 5653 cases and 9115 controls were included in the pooled analysis. Physical activity was harmonised across nine studies and modelled as study‐specific tertiles. Multinomial logistic regression was used to estimate the association between physical activity and NHL, adjusting for confounders. The overall odds of NHL was 13% lower among participants in the most active tertile of MVPA compared to the least active tertile (adjusted odds ratio = 0.87, 95% CI = 0.80, 0.95). Similar decreases were observed across NHL subtypes. In summary, in this pooled analysis of case‐control studies, physical activity was associated with a modest risk reduction for each NHL subtype examined and with overall NHL.